

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



萬桐園

CHINA WAN TONG YUAN (HOLDINGS) LIMITED

中國萬桐園(控股)有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6966)

UPDATE ON DIRECTOR'S INFORMATION PURSUANT TO RULE 13.51B(2) OF THE LISTING RULES

This announcement is made by China Wan Tong Yuan (Holdings) Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51B(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in relation to an update of information of Dr. Wong Wing Kuen, Albert (“**Dr. Wong**”), an independent non-executive director of the Company.

The board of directors (the “**Director(s)**”) of the Company (the “**Board**”) was notified by Dr. Wong that Dexin China Holdings Company Limited (“**Dexin China**”) was ordered to be wound up by the High Court of The Hong Kong Special Administrative Region on 11 June 2024 (the “**Winding-up Order**”) and the Official Receiver was appointed as the provisional liquidator of Dexin China. The Winding-up Order was made upon a winding-up petition filed by China Construction Bank (Asia) Corporation Limited against Dexin China in relation to the non-payment of the 9.95% senior notes due December 2022 issued by Dexin China in the principal amount of US\$350,000,000 and accrued interests. Dr. Wong informed the Company that he has been an independent non-executive director of Dexin China from 11 January 2019 up until 11 June 2024 when he resigned as independent non-executive director of Dexin China with immediate effect.

Based on publicly available information, Dexin China is a company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the Main Board of the Stock Exchange (stock code: 2019) and the trading of which has been suspended from 11 June 2024 and up to the date of this announcement. Dexin China and its subsidiaries are principally engaged in the property development and construction services, property investment and hotel operations in the People's Republic of China. For further

information on the Winding-up Order, please refer to the respective announcements of Dexin China dated 21 March 2024, 5 June 2024 and 12 June 2024 published on the website of the Stock Exchange.

Neither Dexin China nor any of its subsidiaries are related to the Group. As the Winding-up Order did not involve the Group, the Board is of the view that the Winding-up Order has no impact on the business and operations of the Group.

The Board is not in a position to express any opinion on matters relating to the Winding-up Order and has no further information on the Winding-up Order other than those set out above which is based on the information supplied by Dr. Wong and publicly available information.

Dr. Wong confirmed that (i) he has no connection with and no involvement in the matters relating to the Winding-up Order nor any of the underlying claims against Dexin China, save as acting as an independent non-executive director of Dexin China duly and properly exercising his duty of care; and (ii) he is not one of the respondents of the Winding-up Order nor a party to such winding-up proceedings and is not aware of any actual or potential claim that has been or will be made against him as a result of the Winding-up Order. Based on the aforementioned, as at the date of this announcement, the Board is not aware of any impact cast by the Winding-up Order on Dr. Wong's ability to fulfil the duties of an independent non-executive Director.

Dr. Wong has confirmed that save as disclosed in this announcement, there are no other matters which are required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, and he is not aware of any other matters that need to be brought to the attention of the Company and its shareholders.

By order of the Board
China Wan Tong Yuan (Holdings) Limited
Zhao Ying
Chairman

Hong Kong, 17 June 2024

As at the date of this announcement, the Board of the Company comprises the chairman and non-executive Director of the Company, namely Ms. Zhao Ying, three executive Directors of the Company, namely Ms. Li Xingying, Ms. Wang Wei and Mr. Huang Peikun, and three independent non-executive Directors of the Company, namely Mr. Cheung Ying Kwan, Dr. Wong Wing Kuen Albert and Mr. Choi Hon Keung Simon.